Axon Enterprise Inc (OQ:AXON)

Feb 13, 2024 03:01 pm ET
Axon to Release Fourth Quarter 2023 Earnings on February 27, 2024
SCOTTSDALE, Ariz., Feb. 13, 2024 /PRNewswire/ -- Axon (Nasdaq: AXON), the global public safety technology leader, today announced that it will report fourth quarter 2023 financial results after the market closes on Tuesday, February 27, 2024. Axon will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.
Feb 01, 2024 06:00 am ET
Axon Accelerates Real-Time Operations Solution with Strategic Acquisition of Fusus
Acquisition builds on existing partnership, combining Fusus' real-time situational awareness expertise with Axon's innovative public safety technology for enhanced safety in any environment
Jan 25, 2024 03:05 pm ET
Axon Launches Axon Body Workforce, New Body Camera To Protect Frontline Workers
Axon expands public safety technology to protect life in retail and healthcare settingsEarly trials in retail have resulted in a nearly 50% reduction of incident escalations, demonstrating effective and safe de-escalation
Jan 08, 2024 08:00 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Axon Enterprise, Inc. (NASDAQ: AXON) and Encourages Long-Term Investors to Contact the Firm
Shareholder protection law firm Kaskela Law LLC announces that it is investigating Axon Enterprise, Inc. (NASDAQ: AXON) (“Axon”) on behalf of the company’s long-term investors. On August 30, 2023, Reuters published an article entitled “At Taser...
Jan 03, 2024 08:31 am ET
Thinking about buying stock in Sigma Additive Solutions, Axon Enterprise, Bank of America, Aurora Innovation, or TDCX Inc?
NEW YORK, Jan. 3, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SASI, AXON, BAC, AUR, and TDCX.
Dec 26, 2023 09:53 am ET
RETAIL SAFETY DURING THE HOLIDAYS AND BEYOND
Learn about retailer challenges and how law enforcement technology could be used to help mitigate workplace violence and keep employees safe
Nov 28, 2023 03:01 pm ET
Axon Publishes Force for Good Report
With 2023 Report, Axon Celebrates 30 Years of Being a Force For Good, Re-Commits to Protecting Life
Nov 28, 2023 02:30 pm ET
Verizon accelerates network slicing technology with new public safety use case
Verizon, a leader in 5G technology and innovation, and Axon Enterprise Inc., (NASDAQ: AXON), a global public safety technology leader, recently demonstrated the ability to sustain performance levels for mission critical functions while passing...
Nov 07, 2023 03:01 pm ET
Axon reports Q3 2023 revenue up 33% to $414 million, raises outlook
SCOTTSDALE, Ariz. , Nov. 7, 2023 /PRNewswire/ --
Nov 07, 2023 08:15 am ET
AXON SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Axon Enterprise, Inc. (NASDAQ: AXON) and Encourages Long-Term Investors to Contact the Firm
Stockholder law firm Kaskela Law LLC announces that it is investigating Axon Enterprise, Inc. (NASDAQ: AXON) (“Axon”) on behalf of the company’s long-term investors.
Oct 25, 2023 07:30 am ET
Axon to Release Third Quarter 2023 Earnings on November 7, 2023
SCOTTSDALE, Ariz., Oct. 25, 2023 /PRNewswire/ -- Axon (Nasdaq: AXON), the global public safety technology leader, today announced that it will report third quarter 2023 financial results after the market closes on Tuesday, November 7, 2023. Axon will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.
Oct 18, 2023 09:00 am ET
Kaskela Law LLC Announces Shareholder Investigation of Axon Enterprise, Inc. (NASDAQ: AXON) and Encourages Long-Term Investors to Contact the Firm
PHILADELPHIA, Oct. 18, 2023 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Axon Enterprise, Inc. (NASDAQ: AXON) ("Axon") on behalf of the company's long-term investors.  
Oct 16, 2023 07:30 am ET
Axon Launches National Database to Track Gun-Related Deaths Between Police and Public
Axon Public Safety Gun Fatality Database will deliver insights to help inform solutions for moonshot goal to reduce gun-related deaths between police and the public
Oct 10, 2023 07:30 am ET
Axon showcases giant leaps in public safety technology at the International Association of Chiefs of Police Conference
Immersive booth experience highlights new TASER device and body camera and unveils new capabilities with Axon VR Training
Oct 09, 2023 07:30 am ET
Federal Trade Commission Dismisses Antitrust Complaint Against Axon
Unconditional dismissal follows Supreme Court's historic decision to allow Axon's constitutional challenges to the FTC's structure to proceed in federal court
Jul 25, 2023 04:01 pm ET
Axon to Release Second Quarter 2023 Earnings on August 8, 2023
SCOTTSDALE, Ariz., July 25, 2023 /PRNewswire/ -- Axon (Nasdaq: AXON), the global public safety technology leader, today announced that it will report second quarter 2023 financial results after the market closes on Tuesday, August 8, 2023. Axon will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.
Jul 18, 2023 09:00 am ET
Set Jet to Become Public Via Merger with Revelstone Capital Acquisition Corp.
Set Jet, Inc. (“Set Jet”), a membership-based private jet charter program, and Revelstone Capital Acquisition Corp. (“RCAC”) (NASDAQ: RCAC), a publicly traded special purpose acquisition company, announced today that they have entered into a...
Jul 06, 2023 07:30 am ET
Axon Public Safety Technology Roadshow Expands to Nine New Countries
Axon's fully customized trailer hits the road this summer— showcasing the latest public safety solutions across 30 cities
Jul 05, 2023 10:09 am ET
THE WELL-BEING OF FIRST RESPONDERS: A VITAL CALL TO ACTION
LEARN HOW GREATER AWARENESS, SUPPORT AND TOOLS CAN ASSIST FIRST RESPONDERS IN MAINTAINING WELLNESS AND MANAGING THROUGH COMPLEX SITUATIONS 
Jun 28, 2023 07:30 am ET
Axon Supports First Responders with Video Series on Post Traumatic Growth
Axon Aid to offer five-phase video program at no cost to first responders
Jun 08, 2023 07:30 am ET
CHRISTUS Health Becomes Latest Health Network to Deploy Axon Body Cameras to Enhance Hospital Security
Axon Body 3 cameras will be deployed to hospital security in over 60 acute care health centers to promote a safer hospital environment
May 17, 2023 07:30 am ET
San Bernardino County District Attorney's Office Deploys Axon Justice Premier
San Bernardino County in California adopts Axon's digital evidence management system designed specifically for prosecutors and criminal defense lawyers
May 09, 2023 04:01 pm ET
Axon reports Q1 2023 revenue of $343 million, up 34% YOY, raises outlook
SCOTTSDALE, Ariz., May 9, 2023 /PRNewswire/ --
May 01, 2023 06:20 pm ET
Axon Enterprise Set to Join S&P 500; STAG Industrial to Join S&P MidCap 400
NEW YORK, May 1, 2023 /PRNewswire/ -- S&P MidCap 400 constituent Axon Enterprise Inc. (NASD: AXON) will replace First Republic Bank (NYSE: FRC) in the S&P 500, and STAG Industrial Inc. (NYSE: STAG) will replace Axon Enterprise in the S&P MidCap 400 effective prior to the opening of trading on Thursday, May 4. The Federal Deposit Insurance Corp. (FDIC) announced that it has taken First Republic Bank into FDIC Receivership and therefore First Republic Bank is no longer eligible for inclusion.
Apr 25, 2023 04:01 pm ET
Axon to Release First Quarter 2023 Earnings on May 9, 2023
SCOTTSDALE, Ariz., April 25, 2023 /PRNewswire/ -- Axon (Nasdaq: AXON), the global public safety technology leader, today announced that it will report first quarter 2023 financial results after the market closes on Tuesday, May 9, 2023. Axon will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.
Apr 17, 2023 07:30 am ET
Axon Wins Jurisdictional Challenge Against the Federal Trade Commission with Unanimous Supreme Court Decision
Supreme Court issues a 9-0 decision in favor of Axon, allowing constitutional claims to proceed in federal court
Apr 11, 2023 08:02 pm ET
Axon launches next generation body camera with more features to never miss a moment
Axon Body 4 provides better quality footage with additional perspectives, streamlined operations and introduces real-time communications support making it far more than just a camera
Apr 10, 2023 07:30 am ET
Axon Recognizes Public Safety Heroes
Recipients of RISE and Jack Cover Awards will be honored this week at Axon Accelerate, the premier public safety technology conference
Mar 15, 2023 04:01 pm ET
Axon Appoints New Board Members
SCOTTSDALE, Ariz., March 15, 2023 /PRNewswire/ -- Axon (Nasdaq: AXON), the global public safety technology leader, is pleased to announce the appointment of three additional members to its board of directors, Erika Ayers, CEO of Barstool Sports, Graham Smith, former Salesforce executive and Jeri Williams, former Phoenix Police Department Chief of Police. "It's an honor to welcome Ms. Ayers, Mr. Smith and Chief Williams to Axon's board and we look forward to their contributions as we continue to innovate through technology and create solutions for safety that can help protect life," said Axon
Mar 08, 2023 08:34 am ET
Thinking about trading options or stock in Axon Enterprise, Airbnb, Tesla, NVIDIA, or Meta Platforms?
NEW YORK, March 8, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXON, ABNB, TSLA, NVDA, and META.
Feb 07, 2023 03:01 pm ET
Axon to Release Fourth Quarter 2022 Earnings on February 28, 2023
SCOTTSDALE, Ariz., Feb. 7, 2023 /PRNewswire/ -- Axon (Nasdaq: AXON), the global public safety technology leader, today announced that it will report fourth quarter 2022 financial results after the market closes on Tuesday, February 28, 2023. Axon will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.
Jan 24, 2023 12:45 pm ET
Axon Unveils TASER 10
With a 10-probe capacity and maximum range of 45 feet, TASER 10 ushers in a new era of less-lethal technology
Dec 20, 2022 03:01 pm ET
AXON CLOUD UPGRADED TO HIGHEST LEVEL OF SECURITY STATUS BY US GENERAL SERVICES ADMINISTRATION
Authorization deepens Axon's trusted partnership with US federal government agencies
Dec 06, 2022 10:44 pm ET
Axon Announces Upsize and Pricing of Convertible Senior Notes Offering
SCOTTSDALE, Ariz., Dec. 6, 2022 /PRNewswire/ -- Axon Enterprise, Inc. (NASDAQ: AXON) ("Axon") today announced the pricing of its private offering of $600 million aggregate principal amount of 0.50% Convertible Senior Notes due 2027 (the "Notes") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Axon also granted the initial purchasers of the Notes an option to purchase up to an additional $90 million aggregate principal amount of the Notes, for settlement within a 13-day period beginn
Dec 05, 2022 04:00 pm ET
Axon Announces Proposed Convertible Senior Notes Offering
SCOTTSDALE, Ariz., Dec. 5, 2022 /PRNewswire/ -- Axon Enterprise, Inc. (NASDAQ: AXON) ("Axon") today announced that it intends to offer, subject to market and other conditions, $500 million aggregate principal amount of Convertible Senior Notes due 2027 (the "Notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Axon also expects to grant to the initial purchasers of the Notes an option to purchase up to an additional $75 million aggregate principal amount of
Nov 09, 2022 08:35 am ET
Thinking about trading options or stock in Walt Disney, Axon, Zendesk, Tesla, or Kroger?
NEW YORK, Nov. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIS, AXON, ZEN, TSLA, and KR.
Nov 08, 2022 03:01 pm ET
Axon Reports Record Q3 2022 Revenue of $312 Million, Up 34% YOY, Raises Full-Year Outlook
 SaaS strength drives Axon Cloud revenue growth of 51%; Annual Recurring Revenue of $403 million, up 40% YOY EPS of $0.17, Non-GAAP EPS of $0.60, Adjusted EBITDA of $68 million at 21.7% marginSCOTTSDALE, Ariz., Nov. 8, 2022 /PRNewswire/ --
Oct 25, 2022 04:01 pm ET
Axon to Release Third Quarter 2022 Earnings on November 8, 2022
SCOTTSDALE, Ariz., Oct. 25, 2022  /PRNewswire/ -- Axon (Nasdaq: AXON), the global public safety technology leader, today announced that it will report third quarter 2022 financial results after the market closes on Tuesday, November 8, 2022. Axon will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.
Oct 20, 2022 06:26 pm ET
Axon Launches Moonshot Goal and Rallies Support to Cut Gun-Related Deaths Between Police and Public by 50% in 10 Years
Law enforcement and community leaders join Axon in shared commitment
Oct 13, 2022 07:30 am ET
Department of Veterans Affairs to Outfit VA Police with Axon Body, In-Car Cameras
VA to manage program with Axon's digital evidence management solution, Axon Evidence, which is FedRAMP-authorized to securely store government data and digital evidence
Sep 27, 2022 07:30 am ET
Axon Appoints Andrea James as Chief Communications Officer
Awards equity inducement grant to Brittany Bagley, Chief Financial Officer
Sep 07, 2022 07:30 am ET
Wellstar Health Partners with Axon to Enhance Hospital Security and De-Escalation
One of the largest health systems in Georgia to equip security officers with TASER 7 devices, as well as provide de-escalation tools and training, to promote a safer hospital environment
Sep 01, 2022 07:30 am ET
Axon's New Ethics and Equity Advisory Council to Deliver Input from Community Voices on the Development of Public Safety Technologies
Independent council will advise Axon on issues relating to the ethical and equitable development and deployment of new technologies
Aug 19, 2022 07:30 am ET
Fairfax County PD Deploys Axon's My90 Feedback Tool to Better Engage with Community
First Major City Chief's Association member to deploy Axon's My90 platform to collect confidential feedback from community members
Aug 10, 2022 04:15 pm ET
Axon Names Brittany Bagley as New Chief Financial Officer and Chief Business Officer
SCOTTSDALE, Ariz., Aug. 10, 2022 /PRNewswire/ -- Axon (NASDAQ: AXON), the global leader in connected public safety technologies, today announced that it has named Brittany Bagley as its new Chief Financial Officer and the newly created position of Chief Business Officer, effective September 26, 2022. Ms. Bagley replaces Jim Zito, who has been serving as interim Chief Financial Officer since May 4, 2022. Zito will resume his prior role as Senior Vice President of Accounting.
Aug 09, 2022 04:01 pm ET
Axon Reports Record Revenue Up 31% to $286 million; Raises Full-Year Outlook
SaaS Strength: Annual Recurring Revenue of $368 million, up 41%Profit of $0.71 per diluted share, non-GAAP diluted EPS of $0.44, Adjusted EBITDA of $50 millionFuture contracted revenue surpasses $3 billionSCOTTSDALE, Ariz., Aug. 9, 2022 /PRNewswire/ --
Jul 27, 2022 07:30 am ET
Axon to Release Second Quarter 2022 Earnings on August 9, 2022
SCOTTSDALE, Ariz., July 27, 2022 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that it will report second quarter 2022 financial results after the market closes on Tuesday, August 9, 2022. Axon will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.
Jul 18, 2022 07:30 am ET
Several Major Cities Across Canada to Deploy Axon's TASER 7 Device
To date, over 50 agencies in Canada are now using TASER 7, keeping both officers and communities safe
Jul 18, 2022 07:30 am ET
Several Major Cities Across Canada to Deploy Axon's TASER 7 Device
To date, over 50 agencies in Canada are now using TASER 7, keeping both officers and communities safe
Jul 13, 2022 07:30 am ET
Axon Appoints Isaiah Fields as Chief Legal Officer
SCOTTSDALE, Ariz., July 13, 2022 /PRNewswire/ -- Axon (NASDAQ: AXON), the global leader in connected public safety technologies, today announced the appointment of Isaiah Fields to the role of Chief Legal Officer (CLO). In this role, Fields will spearhead Axon initiatives across legal operations, government affairs, risk management and compliance.
Jun 09, 2022 07:30 am ET
Axon Appoints Josh Isner as Chief Operating Officer
Seasoned executive to help drive Axon's next phase of growth
Jun 02, 2022 07:30 am ET
Axon Announces TASER Drone Development to Address Mass Shootings
Remotely operated, non-lethal drones key in long-term plan to detect and stop mass shootings in less than 60 seconds
May 25, 2022 07:30 am ET
Axon Announces 2022 RISE Award Winners
SCOTTSDALE, Ariz., May 25, 2022 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced the 2022 winners of the Axon RISE Awards. Designed to honor public safety and community organizations, the Axon RISE Awards highlight the untold stories of the everyday heroes among us. The 2022 winners are as follows:
May 24, 2022 07:30 am ET
Axon Announces Availability of VR Simulator Training for Public Safety to Increase De-Escalation Training
Phoenix PD among first police agencies to roll out new virtual reality training to officers
May 23, 2022 07:30 am ET
Axon and Skydio Announce New Integration of Skydio Autonomous Drones with Axon Respond for Public Safety
This partnership will streamline evidence management and enable real-time situational awareness for public safety
May 19, 2022 07:30 am ET
Axon and Fūsus Partner to Provide Enhanced Real-Time Community Policing Solutions
Partnership allows public safety agencies opportunity to solve crimes faster by bringing together live video, and sensor data from Axon and Fūsus into a single view via both Axon Respond and Fūsus Real-Time Crime Center
May 10, 2022 04:01 pm ET
Axon Reports Q1 2022 Revenue Up 32% to $256 million, Raises Full Year Outlook
Axon Cloud revenue up 47% on strong SaaS demand Net income of $55 million, Adjusted EBITDA of $49 million Operating cash flow of $44 million, adjusted free cash flow of $32 million SCOTTSDALE, Ariz., May 10, 2022 /PRNewswire/ --
May 04, 2022 04:02 pm ET
Axon to Release First Quarter 2022 Earnings on May 10, 2022
SCOTTSDALE, Ariz., May 4, 2022  /PRNewswire/ --  Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that it will report first quarter 2022 financial results after the market closes on Tuesday, May 10, 2022. Axon will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.The live webinar to discuss financial results, followed by Q&A, will be linked from Axon's investor relations website at https://investor.axon.com. An archived replay will be available after the call ends. Upcoming Conference Parti
May 04, 2022 04:01 pm ET
Axon Announces CFO Transition
Jim Zito Appointed Interim Chief Financial Officer
Apr 18, 2022 07:30 am ET
Columbus PD Partners with Axon to Outfit Officers with Next Generation In-Car and Body Camera Technology
SCOTTSDALE, Ariz., April 18, 2022 /PRNewswire/ --  Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that the Columbus Division of Police (OH), a Major Cities Chiefs Association member, has signed a 5-year contract with Axon to deploy 2,000 Axon Body 3 cameras, 75 Axon Flex 2 cameras, 15 Axon Interview systems, 460 Axon Fleet 3 in-car camera systems featuring Axon's AI-powered automated license plate reader (ALPR) and 2,017 licenses for Axon Evidence, Axon's digital evidence management system. The agency will also receive unlimited 3rd party stor
Apr 12, 2022 07:30 am ET
Axon Announces New Community Coalition Members; Coalition Continues Work Promoting Responsible Development of Public Safety Technologies
Axon formed the Community Advisory Coalition with the goal of connecting with representatives from our nation's diverse and untapped communities and creating cutting-edge solutions that provide equitable outcomes
Apr 06, 2022 04:30 pm ET
Axon Announces Acquisition of Virtual Reality Training Studio 'Foundry 45'
SCOTTSDALE, Ariz., April 6, 2022 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced the acquisition of Foundry 45, an industry-leading virtual reality (VR) studio focused on developing immersive training modules for large enterprises. The acquisition, which closed on April 5, 2022, will integrate Foundry 45 into the Axon VR team.
Mar 31, 2022 07:30 am ET
São Paulo State Military Police to Deploy 7,000 Additional Axon Body 3 Cameras After Significant Increase in Lives Saved
After 85% drop in police lethality rates with body-worn cameras, Brazil's largest law enforcement agency purchased an additional 7,000 Axon Body 3 cameras featuring Axon Respond
Mar 24, 2022 04:01 pm ET
Fresno PD First Major City to Deploy Axon Dispatch to Better Support First Responders
Axon Dispatch provides a robust 9-1-1 computer-aided dispatch system (CAD) built on modern cloud technologies
Mar 17, 2022 07:30 am ET
Axon Announces First Body-Worn Camera Deployment in the Maldives
Maldives Police Service has deployed Axon body-worn cameras with real-time situational awareness and digital evidence management to enhance public safety and strengthen accountability and transparency
Feb 24, 2022 03:01 pm ET
Axon Reports 2021 Results: Third Straight Year of 25%+ Revenue Growth
SCOTTSDALE, Ariz., Feb. 24, 2022 /PRNewswire/ --
Feb 17, 2022 06:30 am ET
Axon to Release Fourth Quarter 2021 Earnings on February 24, 2022
SCOTTSDALE, Ariz., Feb. 17, 2022 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that it will report fourth quarter 2021 financial results after the market closes on Thursday, February 24, 2022. Axon executives Rick Smith, CEO and founder; Luke Larson, president; and Jawad Ahsan, CFO; will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.
Feb 08, 2022 03:00 am ET
Axon Announces New European R&D Office in London
LONDON and SEATTLE, Feb. 8, 2022 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced it will continue its global expansion by opening its first European research and development (R&D) office in London.
Jan 31, 2022 03:01 pm ET
Axon Director Dr. Richard Carmona Spearheads Shareholder-Friendly Governance Proposals; Concludes 15 Years of Board Service
SCOTTSDALE, Ariz., Jan. 31, 2022 /PRNewswire/ -- Axon (NASDAQ: AXON), the global leader in connected public safety technologies, today announced that Dr. Richard Carmona, the 17th US Surgeon General, will be retiring from Axon's board after 15 years of serving as a director. He will stay on through the spring 2022 shareholder meeting to oversee Axon's implementation of several important governance changes.
Jan 18, 2022 06:30 am ET
Axon Announces New Consumer TASER Device That Alerts Emergency Dispatch When Fired
SCOTTSDALE, Ariz., Jan. 18, 2022 /PRNewswire/ -- TASER Self-Defense, the consumer division of Axon Enterprise, Inc. (Nasdaq: AXON), the global leader in connected public safety technologies, today announced the TASER Bolt 2, the latest energy weapon in its self-defense product line.
Jan 12, 2022 06:30 am ET
Dutch National Police Now Largest Netherlands Agency to Deploy TASER Devices
SCOTTSDALE, Ariz., Jan. 12, 2022 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that the Dutch National Police (DNP) will equip officers in basic policing across the country with TASER conducted energy devices (CEDs) as a critical safety and de-escalation tool to safely handle situations and reduce injuries to officers and the public.
Dec 15, 2021 06:30 am ET
PRIMECorp Selects Axon Evidence to Connect All Police Services Across British Columbia
SCOTTSDALE, Ariz., Dec. 15, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, and its subsidiary, Axon Public Safety Canada, Inc., today announced PRIMECorp, will be deploying Axon's digital evidence management solution, Axon Evidence, to all supported police services in British Columbia. This groundbreaking modernization initiative will connect British Columbia justice sector partners and stakeholders, including the police and crown attorneys.
Dec 15, 2021 06:30 am ET
PRIMECorp Selects Axon Evidence to Connect All Police Services Across British Columbia
PRIMECorp partnership with Axon is the largest Axon Evidence software only deal
Dec 08, 2021 06:30 am ET
Axon Introduces Axon Attorney Premier; the First Digital Evidence Management System Designed Specifically For Prosecutors and Defense Attorneys
SCOTTSDALE, Ariz., Dec. 8, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced the launch of Axon Attorney Premier, the first digital evidence management system designed specifically to streamline the discovery process for prosecutors and defense attorneys.
Nov 15, 2021 03:01 pm ET
Axon Reports Record Bookings of $0.5B in Q3, Up 70% YTD; Q3 Revenue up 39%; Raises 2022 Revenue Outlook to $1 Billion
SCOTTSDALE, Ariz., Nov. 15, 2021 /PRNewswire/ --
Nov 04, 2021 04:01 pm ET
Axon Announces Revised Date for Third Quarter 2021 Earnings Release and Conference Call
SCOTTSDALE, Ariz., Nov. 4, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that its third quarter 2021 earnings release and conference call has been rescheduled to allow additional time to complete its Quarterly Report on Form 10-Q. The delay is associated with the Company's implementation of multiple phases of its Enterprise Resource Planning ("ERP") and related systems, which were completed and went live during the third quarter.
Nov 03, 2021 07:30 am ET
Axon Announces 2021 RISE Award Winners
SCOTTSDALE, Ariz., Nov. 3, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced the winners of the 2021 Axon RISE Awards. Designed to honor those in public safety and community organizations, the RISE Awards highlight the untold stories of the everyday heroes among us. The 2021 winners are as follows:
Nov 02, 2021 07:30 am ET
Axon and Fotokite Bring Actively Tethered Autonomous Drones with Livestreaming and Evidence Management to Public Safety Today
SCOTTSDALE, Ariz., Nov. 2, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, in partnership with Fotokite, a service provider of actively tethered Unmanned Aerial System (UAS) solutions, commonly referred to as drones, and public safety software tools, today announced the autonomous Fotokite Sigma UAS complete with wireless livestreaming and evidence management is now commercially available to public safety customers in the US and Canada. For more information on pricing visit: https://www.axon.com/products/axon-air/fotokite The exclusive par
Oct 26, 2021 07:30 am ET
Axon to Release Third Quarter 2021 Earnings on November 9, 2021
SCOTTSDALE, Ariz., Oct. 26, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that it will report third quarter 2021 financial results after the market closes on Tuesday, November 9, 2021. Axon executives Rick Smith, CEO and founder; Luke Larson, president; and Jawad Ahsan, CFO; will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.
Oct 19, 2021 07:30 am ET
Scottish Government Selects Axon Evidence to Connect All Public Safety Stakeholders
SCOTTSDALE, Ariz., Oct. 19, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies and its United Kingdom subsidiary, Axon Public Safety UK, today announced that the Scottish Government has selected Axon's digital evidence management solution, Axon Evidence, as part of their commitment to invest in the development of a Digital Evidence Sharing Capability (DESC) for Scotland's public safety authorities.
Oct 12, 2021 07:30 am ET
Air National Guard to Renew TASER Device Program
SCOTTSDALE, Ariz., Oct. 12, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, announced today that the Air National Guard, the reserve branch of the U.S. Air Force, will renew its TASER device program and deploy roughly 5,000 TASER X26P energy weapons to reserve troops. With this order, the Air National Guard will replace the TASER X26E devices currently in use. This order was received in Q3 2021.
Sep 24, 2021 07:30 am ET
Axon Announces Microsoft, Skydio and Verizon as Top Sponsors for 2021 Accelerate Conference
SCOTTSDALE, Ariz., Sept. 24, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced Microsoft as the title sponsor of Axon Accelerate, the public safety technology conference. Skydio, Verizon, FirstNet Built with AT&T, Cellebrite, Cradlepoint, and Panasonic TOUGHBOOK are among other confirmed sponsors for the annual conference taking place in Phoenix, on November 1 to 3. To learn more and register, visit www.axon.com/accelerate.
Sep 22, 2021 07:30 am ET
Puebla Municipal Police Partners with Axon for Largest TASER Device Deployment in Mexico
SCOTTSDALE, Ariz., Sept. 22, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that Puebla Municipal Police Department will equip officers with TASER conducted electrical devices (CEDs) as a critical de-escalation tool to safely handle situations and reduce injuries to officers and the public.
Aug 31, 2021 07:30 am ET
Six Flags Entertainment Partners With Axon To Implement Body-Worn Cameras At All U.S. Park Locations
SCOTTSDALE, Ariz., Aug. 31, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that Six Flags Entertainment Corp., has equipped security staff across U.S. amusement park locations with body-worn cameras backed by Axon's digital evidence management solution, Axon Evidence. This order was received and shipped in Q2 of 2021.
Aug 25, 2021 07:30 am ET
Axon Furthers Commitment to Community Engagement with Acquisition of My90
SCOTTSDALE, Ariz., Aug. 25, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced it has acquired My90, Inc., which collects anonymized community feedback to generate actionable insights to help police agencies improve trust, safety and equity.
Aug 24, 2021 07:30 am ET
Gujarat State Police Joins the Axon Network with Largest Body-Worn Camera Rollout in India
SCOTTSDALE, Ariz., Aug. 24, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced the Gujarat State Police will equip officers throughout Gujarat, India with 10,350 body-worn cameras and Axon's digital evidence management solution.
Aug 09, 2021 07:30 am ET
TASER Self-Defense Partners with Kryptek to Launch Limited Edition Personal Self-Defense Product
SCOTTSDALE, Ariz., Aug. 9, 2021 /PRNewswire/ -- TASER Self-Defense, the consumer division of Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced the release of its new self-defense product, the TASER Pulse: Kryptek Edition, featuring a unique camouflage pattern from Kryptek's Altitude line.
Aug 05, 2021 04:01 pm ET
Axon Q2 2021 Revenue of $219 Million Up 55%; International Revenue Grows 60%; Raising Outlook
SCOTTSDALE, Ariz., Aug. 5, 2021 /PRNewswire/ --
Aug 03, 2021 09:00 am ET
Aira Closes $12 Million Seed Investment to Accelerate Adoption of FreePower® Wireless Charging
CHANDLER, Ariz., Aug. 3, 2021 /PRNewswire/ -- Aira Inc., the company redefining wireless charging with FreePower®, today announced a $12 million Series Seed funding round. This additional capital will accelerate the company's expansion into the automotive, enterprise, and hospitality sectors. It will also enable Aira — which was named FastCompany's #5 Most Innovative Company in 2021 — to expand its operational and engineering resources in preparation for the launch of FreePower® 2.0 by year's end. The company was recently granted it's first patents for FreePower® and has more than 80 patent
Jul 22, 2021 07:30 am ET
Axon to Release Second Quarter 2021 Earnings on August 5, 2021
SCOTTSDALE, Ariz., July 22, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that it will report second quarter 2021 financial results after the market closes on Thursday, August 5, 2021. Axon executives Rick Smith, CEO and founder; Luke Larson, president; and Jawad Ahsan, CFO; will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.
Jul 16, 2021 07:30 am ET
Virginia Beach PD Latest MCCA Member to Join the Axon Network
SCOTTSDALE, Ariz., July 16, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies today announced that the Virginia Beach Police Department has signed a 10-year contract with Axon to deploy TASER 7 energy weapons and body-worn cameras as a part of the Officer Safety Plan 7+(OSP 7+) Premium bundle. Virginia Beach, VA, a Major Cities Chiefs Association (MCCA) member, is the 55th MCCA agency to have joined the Axon Network.
Jul 13, 2021 07:30 am ET
Italy to Deploy Axon TASER Devices for the First Time to Officers Nationwide
SCOTTSDALE, Ariz., July 13, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, announced today that it has been awarded the national tender to supply TASER conductive electrical devices (CEDs) to law enforcement agencies across Italy. Under terms of the contract, signed in early July 2021, 4,482 TASER CEDs will be deployed to Italian forces of Polizia di Stato, Arma dei Carabinieri and Guardia di Finanza by the end of the year.
Jul 09, 2021 07:30 am ET
Toronto Police Service to Expand TASER Device Program
Toronto Police Service (TPS) will deploy an additional 1,728 Axon TASER 7 Conducted Energy Devices (CEDs) to officers across the city, bringing overall TASER device deployment to 2,350 units
Jul 09, 2021 07:30 am ET
Toronto Police Service to Expand TASER Device Program
Toronto Police Service (TPS) will deploy an additional 1,728 Axon TASER 7 Conducted Energy Devices (CEDs) to officers across the city, bringing overall TASER device deployment to 2,350 units
Jul 02, 2021 03:37 pm ET
Axon and DroneSense Partner to Bring State-of-the-Art Situational Awareness and UAS Management Software to Public Safety
Axon (Nasdaq: AXON), the global leader in connected public safety technologies and DroneSense, the leading software platform for drones in public safety, today announced a strategic partnership to jointly provide public safety agencies with a...
Jun 30, 2021 07:30 am ET
Axon Fleet 3 Has Arrived: Next Generation In-Car Video System with ALPR Now Shipping to Public Safety Agencies
SCOTTSDALE, Ariz., June 30, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that its next generation Fleet 3 in-car video system is now shipping to customers. Built from the ground up with ethics in mind, the in-car video system features Axon's AI-powered ALPR service along with real-time situational awareness through Axon Respond for Devices, fundamentally raising the bar on what agencies should expect from in-car video systems. Axon has partnered with industry leaders Flock Safety, Cradlepoint, and Airgain to make the Fle
Jun 29, 2021 07:30 am ET
Piedmont Healthcare Partners with Axon to Provide De-escalation Tools to Hospitals
SCOTTSDALE, Ariz., June 29, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, announced today that Piedmont Healthcare will equip hospital security officers across several Georgia hospital campuses with TASER 7 energy weapons, Axon Body 3 cameras and licenses to the digital evidence management solution, Axon Evidence.
Jun 15, 2021 07:30 am ET
Axon and DroneSense Partner to Bring State-of-the-Art Situational Awareness and Drone Management Software to Public Safety
SEATTLE, June 15, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies and DroneSense, the leading software platform for drones in public safety, today announced a strategic partnership to provide public safety agencies with an end-to-end drone software solution, including piloting, administration, evidence management and live streaming.
Jun 10, 2021 07:30 am ET
São Paulo State Military Police Partners with Axon to Implement Largest Body-Worn Camera and Digital Evidence Management Project in Latin America
SCOTTSDALE, Ariz., June 10, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that São Paulo State Military Police (PMESP) has equipped 2,500 officers with Axon Body 3 cameras backed by the digital evidence management solution, Axon Evidence (Evidence.com). PMESP is the first police agency in Brazil to adopt technology that integrates body-worn cameras with an end-to-end cloud-based evidence management platform.
Mar 03, 2021 09:30 am ET
Government of Ontario Deploys Axon Evidence Across Public Safety Agencies
Ontario is the first Province in Canada to connect all justice sector partners and stakeholders via Canadian cloud-based software-as-a-service, Axon Evidence, and other innovative applications including Axon Citizen
Mar 02, 2021 08:00 am ET
Thunder Bay Police Service to Outfit Officers with Body Cameras, Training and De-escalation Tools
TBPS joins the Axon network to enhance public safety and strengthen accountability and transparency
Feb 25, 2021 03:01 pm ET
Axon (AXON) Reports 2020 Revenue of $681 Million, Up 28%, Raises 2021 Outlook
SCOTTSDALE, Ariz., Feb. 25, 2021 /PRNewswire/ --
Feb 11, 2021 06:30 am ET
Axon to Release Fourth Quarter and Full Year 2020 Earnings on February 25, 2021
SCOTTSDALE, Ariz., Feb. 11, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced that it will report fourth quarter and full year 2020 financial results after the market closes on Thursday, February 25, 2021. Axon executives Rick Smith, CEO and founder; Luke Larson, president; and Jawad Ahsan, CFO; will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.
Feb 09, 2021 06:30 am ET
Axon and Cellebrite Partner to Help Manage and Safeguard Digital Intelligence
Data collected and reviewed with Cellebrite Solutions now seamlessly unified in Axon Evidence, allowing investigators to reshape how digital evidence is managed
Feb 09, 2021 06:30 am ET
Axon and Cellebrite Partner to Help Manage and Safeguard Digital Intelligence
Data collected and reviewed with Cellebrite Solutions now seamlessly unified in Axon Evidence, allowing investigators to reshape how digital evidence is managed
Feb 09, 2021 06:30 am ET
Axon And Cellebrite Partner to Help Manage and Safeguard Digital Intelligence
SCOTTSDALE, Ariz., Feb. 9, 2021 /PRNewswire/ -- Axon (Nasdaq: AXON), the global leader in connected public safety technologies, today announced a joint partnership with Cellebrite, the global leader in Digital Intelligence, to streamline investigative workflows for investigators. With this partnership, the digital data collected, analyzed and reviewed by Cellebrite's platform will now integrate seamlessly with Axon's digital evidence management solution, Axon Evidence, providing law enforcement with one place to manage, review and safeguard all digital evidence.
Jan 28, 2021 06:30 am ET
Axon Public Safety Canada Announces Partnership with Canada Beyond the Blue
Beyond the Blue is dedicated to strengthening and supporting families of law enforcement officers in Canada
Feb 14, 2019 07:00 am ET
Axovant Announces Formation of Arvelle Therapeutics and Strategic Transition of Legacy Small Molecule Team Into Newly Formed Company
Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announces the formation of Arvelle Therapeutics and the strategic transition of its legacy small molecule team into the newly-formed company....
Feb 07, 2019 04:15 pm ET
Axovant Announces Third Fiscal Quarter 2018 Financial Results and Corporate Updates
Axovant Sciences (NASDAQ: AXON), a clinical-stage company developing innovative gene therapies, today provided financial results and corporate updates for its third fiscal quarter and nine months ended December 31, 2018. “With the addition of new...
Jan 03, 2019 07:00 am ET
Axovant Announces Presentation at J.P. Morgan Healthcare Conference and Anticipated 2019 Clinical Development Milestones
Axovant Sciences (NASDAQ: AXON), a clinical-stage company developing innovative gene therapies, today announced that the company will be presenting at the 37th Annual J.P. Morgan Healthcare Conference. Pavan Cheruvu, M.D., chief executive officer,...
Jan 02, 2019 07:00 am ET
Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
NEW YORK and BASEL, Switzerland, Jan. 2, 2019 /PRNewswire/ -- Roivant Sciences today announced that Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant, will present an overview of the business as well as new data updates from private companies in the Roivant family at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Dec 26, 2018 07:25 am ET
Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation (NYSE:CGC), ArQule, Inc. (NASDAQ:ARQL),...
Dec 19, 2018 06:00 am ET
Roivant Sciences and Daiichi Sankyo Enter into Broad Pipeline Partnership
NEW YORK and BASEL, Switzerland, Dec. 19, 2018 /PRNewswire/ -- Roivant Sciences today announced that it has entered into a collaboration with Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) to facilitate the out-licensing of investigational medicines. Under the terms of the agreement, Roivant will have the option to obtain exclusive licenses for certain development programs from Daiichi Sankyo on prespecified terms contingent on phase of development.
Dec 14, 2018 09:00 am ET
Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares
Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced the pricing of its underwritten public offering of 30,000,000 of its common shares at a price to the public of $1.00 per share. Gross proceeds to Axovant from the offering are expected to...
Dec 13, 2018 04:56 pm ET
Axovant Sciences Announces Public Offering of Common Shares
Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of the common shares are being offered by Axovant. In connection with this offering, Axovant expects to...
Dec 13, 2018 04:01 pm ET
Axovant Licenses Investigational Gene Therapies for GM1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases from University of Massachusetts Medical School
Axovant Sciences (NASDAQ: AXON), a clinical-stage company focused on innovative gene therapies for neurological and neuromuscular diseases, today announced that it has licensed exclusive worldwide rights for the development and commercialization of...
Dec 10, 2018 07:00 am ET
Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder
Axovant Sciences (NASDAQ: AXON) a clinical-stage gene therapy company, today reported topline results of the 34-patient, exploratory phase 2 clinical study of nelotanserin for the treatment of REM sleep behavior disorder (RBD) in patients with Lewy...
Dec 06, 2018 07:00 am ET
Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD for Parkinson’s Disease and Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial
Axovant Sciences (NASDAQ: AXON), a clinical-stage company developing innovative gene therapies for neurological conditions, today announced feedback from a face-to-face pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding...
Nov 26, 2018 01:00 pm ET
Roivant Launches Aruvant Sciences and Roivant Foundation in Partnership with Cincinnati Children's Hospital Medical Center
BASEL, Switzerland and CINCINNATI, Nov. 26, 2018 /PRNewswire/ -- Roivant Sciences and Cincinnati Children's Hospital Medical Center today announced the launch of Aruvant Sciences, a biopharmaceutical company focused on developing innovative gene therapies for hematological conditions, and the formation of a new nonprofit foundation with the mission of improving access to medical care for patients with sickle cell disease in the developing world. The launch of Aruvant builds on a partnership between Roivant and Innovation Ventures, the commercialization arm of Cincinnati Children's, dating ba
Nov 26, 2018 08:00 am ET
Axovant Stengthens Team with Additional Expertise to Support Gene Therapy Pipeline
Axovant Sciences (NASDAQ: AXON), a company developing innovative gene therapies for neurological and neuromuscular diseases, today announced the addition of five senior team members to strengthen its expertise in the development and...
Nov 07, 2018 04:05 pm ET
Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates
Axovant Sciences (NASDAQ: AXON) today provided financial results and corporate updates for its second fiscal quarter ended September 30, 2018. “We are pleased with the expansion of our gene therapy pipeline and continued evidence of execution...
Oct 25, 2018 02:00 am ET
Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease
Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, today announced dosing of the first patient in a clinical study of AXO-Lenti-PD (also known as OXB-102), an investigational...
Oct 19, 2018 09:10 am ET
New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin — Factors of Influence, Major Initiatives and
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Axovant Sciences Ltd....
Oct 09, 2018 09:02 am ET
Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy
Axovant Sciences (NASDAQ:AXON), a gene therapy company developing innovative treatments for debilitating neurologic and neuromuscular diseases,  today announced upcoming presentations regarding its investigational gene therapy programs,...
Sep 20, 2018 07:00 am ET
Axovant to Present at Two Upcoming Investor Conferences
Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies Gene Therapy Summit 2018 on September 27, 2018 at 9:45 a.m. ET. Additionally, Dr. Cheruvu will...
Sep 17, 2018 09:00 am ET
Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases
BASEL, Switzerland and SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Roivant Sciences today announced the launch of Respivant Sciences, a biopharmaceutical company focused on improving the lives of patients suffering from serious respiratory diseases. Respivant will be led by Chief Executive Officer Bill Gerhart, Executive Vice President for Clinical and Regulatory Ahmet Tutuncu, MD, PhD, and Executive Vice President for Development and Manufacturing Pravin Soni, PhD.
Aug 29, 2018 07:00 am ET
Axovant to Present at Upcoming Investor Conferences
Axovant Sciences (NASDAQ: AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in two upcoming investor conferences.   Dr Cheruvu will present a corporate overview at the H.C. Wainwright 20th Annual Global...
Aug 07, 2018 04:05 pm ET
Axovant Announces First Fiscal Quarter 2018 Financial Results and Corporate Update
Axovant Sciences (NASDAQ:AXON) today announced corporate updates and financial results for its first fiscal quarter ended June 30, 2018. “Axovant is methodically rebuilding its clinical pipeline with the goal of becoming a leader in neurological...
Jul 08, 2018 08:18 pm ET
Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma
Axovant Sciences (NASDAQ:AXON) today announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy (OPMD), and...
Jun 18, 2018 08:30 am ET
Axovant to Present at First Annual Roivant Pipeline Day
Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first annual Roivant Pipeline Day on July 10, 2018 at 4:30 p.m. ET. A live webcast will be available in the...
Jun 07, 2018 09:31 am ET
Thinking about buying stock in Axovant Sciences, Cronos Group, Micron, Netflix or AT&T?
CHICAGO, June 7, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXON, CRON, MU, NFLX, and T.
Jun 06, 2018 02:00 am ET
Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition
Axovant Sciences (NASDAQ:AXON) today announced that it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from Oxford BioMedica. AXO-Lenti-PD is an investigational gene therapy for Parkinson’s...
May 31, 2018 07:00 am ET
Axovant to Present at Two Upcoming Investor Conferences
Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies 2018 Global Healthcare Conference on June 7, 2018 at 9:00 a.m. ET, and at the JMP Securities Life...
May 29, 2018 07:00 am ET
Axovant Strengthens Management Team and Completes Organizational Restructuring in Preparation for Pipeline Expansion
Axovant Sciences (NASDAQ:AXON) today announced that Gavin Corcoran, MB BCh, FACP, will join the Company as Executive Vice President of Research Development, and Michael Hayden, MB ChB, PhD, FRSC, has been appointed as a senior scientific advisor...
Feb 14, 2018 09:00 am ET
AXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences Ltd. Investors
Law Offices of Howard G. Smith commences an investigation on behalf of Axovant Sciences Ltd. (“Axovant Sciences” or the “Company”) (NASDAQ: AXON) investors concerning the Company and its officers’ possible violations of federal securities laws.
Feb 12, 2018 07:00 am ET
Axovant Sciences Announces Changes to Management Team and Board of Directors
BASEL, Switzerland, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Chief Executive Officer David Hung, M.D., has resigned to pursue other opportunities and has also resigned from the Company’s board of directors. In addition,...
Jan 09, 2018 07:00 am ET
CORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
BASEL, Switzerland, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced a correction to the data related to the Company’s investigational drug nelotanserin previously reported in its January 8, 2018 press release. In the results of...
Jan 08, 2018 07:41 am ET
Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
-- Intepirdine Program to be Discontinued Based on MINDSET, HEADWAY, and Gait and Balance Study Results ---- Company to Advance to Larger Confirmatory Nelotanserin DLB Study Focused on Motor Function and Psychosis ---- Conference Call Today at 8:00 a.m. EST --
Jan 08, 2018 07:00 am ET
Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
-- Intepirdine Program to be Discontinued Based on MINDSET, HEADWAY, and Gait and Balance Study Results ---- Company to Advance to Larger Confirmatory Nelotanserin DLB Study Focused on Motor Function and Psychosis ---- Conference Call Today at 8:00 a.m. EST --
Jan 05, 2018 07:00 am ET
Axovant to Present at 36th Annual J.P. Morgan Healthcare Conference
BASEL, Switzerland, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that its Chief Executive Officer David Hung, MD, will be presenting at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th at 10:00...
Nov 02, 2017 04:30 pm ET
Axovant Announces Second Fiscal Quarter Financial Results and Corporate Updates
BASEL, Switzerland, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq:AXON) today announced financial results for its second fiscal quarter and first half ended September 30, 2017, and provided an update on its clinical programs....
Nov 02, 2017 04:30 pm ET
Axovant Announces Second Fiscal Quarter Financial Results and Corporate Updates
BASEL, Switzerland, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq:AXON) today announced financial results for its second fiscal quarter and first half ended September 30, 2017, and provided an update on its clinical programs.
Sep 26, 2017 08:00 am ET
Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease
BASEL, Switzerland, Sept. 26, 2017 /PRNewswire/ -- Axovant Sciences (NASDAQ: AXON) today announced that the Phase 3 MINDSET clinical trial of its investigational drug intepirdine in patients with mild to moderate Alzheimer's disease (AD) who were receiving background donepezil therapy did not meet its co-primary efficacy endpoints. At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition or in measures of activities of daily living as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and by the Alzheimer's Disease Co
Sep 06, 2017 08:00 am ET
Axovant to Present at Two Upcoming Investor Conferences
BASEL, Switzerland, Sept. 6, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced upcoming presentations by David Hung, M.D., chief executive officer of Axovant, on September 6, 2017 at 12:50 p.m. ET at the Baird 2017 Global Healthcare Conference, and on September 12, 2017 at 10:35 a.m. ET at the Morgan Stanley Global Healthcare Conference.
Aug 21, 2017 05:15 pm ET
Axovant to Move Stock Exchange Listing to Nasdaq
BASEL, Switzerland, Aug. 21, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced that it will voluntarily move its stock exchange listing from the New York Stock Exchange to the Nasdaq Global Select Market. The move is expected to become effective on or about September 6th, 2017, and the Company's common shares will continue to trade under the ticker symbol "AXON."
Aug 07, 2017 08:00 am ET
Axovant Announces Fiscal First Quarter Financial Results and Corporate Updates
BASEL, Switzerland, Aug. 7, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced financial results for the three months ended June 30, 2017 as well as general business updates.
Jul 19, 2017 09:00 am ET
New Preclinical Data for Intepirdine Suggests Potential Neuroprotective Properties
BASEL, Switzerland, July 19, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced new data from a preclinical study which suggests that intepirdine may have neuroprotective properties against vascular injury and neuronal metabolic dysfunction (poster P4-588). These results, along with other presentations relating to its intepirdine, nelotanserin and pipeline programs, were presented at the 2017 Alzheimer's Association International Conference (AAIC) being held in London July 16 – 20.
Jul 10, 2017 09:45 am ET
Dermavant Sciences Appoints Dr. Jacqualyn Fouse as Executive Chairman
BASEL, Switzerland, July 10, 2017 /PRNewswire/ -- Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapies in medical dermatology, today announced the appointment of Dr. Jacqualyn "Jackie" Fouse as Executive Chairman.
Jul 10, 2017 09:00 am ET
Axovant to Present Key Intepirdine and Nelotanserin Data at Alzheimer's Association International Conference
BASEL, Switzerland, July 10, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced a number of upcoming presentations relating to its intepirdine and nelotanserin programs at the 2017 Alzheimer's Association International Conference (AAIC) being held in London July 16 – 20.
Jun 19, 2017 08:00 am ET
FDA Grants Fast Track Designation to Axovant's Nelotanserin for Visual Hallucinations in Dementia with Lewy Bodies
BASEL, Switzerland, June 19, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug nelotanserin for the treatment of visual hallucinations disorder in dementia with Lewy bodies (DLB).
Jun 13, 2017 08:00 am ET
Axovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates
BASEL, Switzerland, June 13, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), today reported financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2017, as well as general business updates.
Jun 06, 2017 08:30 am ET
Axovant Announces Changes to Board of Directors
BASEL, Switzerland, June 6, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced that it has appointed Patrick Machado to the Company's Board of Directors effective as of June 15, 2017, while Lawrence Olanoff, MD, and Gary Pisano, Ph.D., have stepped down as directors effective as of the June 1, 2017 board meeting.
Jun 06, 2017 08:30 am ET
Axovant Strengthens Executive Team with Key Management Appointments
BASEL, Switzerland, June 6, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced that it has made several key senior management hires to strengthen its executive team. Stephen Mohr has joined the Company as general counsel; Eric Floyd, Ph.D., as senior vice president, regulatory affairs; Thomas Templeman, Ph.D., as senior vice president, pharmaceutical operations and quality assurance; Mark Wadley as senior vice president, U.S. business; and Samina Bari as vice president, corporate communications. In addition, the Company appointed current executive team member Shankar Ramaswam
May 31, 2017 05:30 pm ET
Axovant Sciences to Present at Upcoming Investor Conferences
BASEL, Switzerland, May 31, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), today announced upcoming presentations at two investor conferences:
Apr 17, 2017 05:15 pm ET
Axovant Sciences Ltd. Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares
BASEL, Switzerland, April 17, 2017 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON) ("Axovant"), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the closing of its underwritten public offering of 7,753,505 of its common shares at a price to the public of $18.54 per common share, including 1,011,326 common shares sold pursuant to the underwriters' exercise in full of their option to purchase additional common shares. Gross proceeds to Axovant from the offering were approximately $143.7 million, before deducting underwriting discounts
Apr 11, 2017 08:00 am ET
Axovant Sciences Ltd. Announces Pricing of $125M Public Offering of Common Shares
BASEL, Switzerland, April 11, 2017 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON) ("Axovant"), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the pricing of its underwritten public offering of 6,742,179 of its common shares at a price to the public of $18.54 per share. Gross proceeds to Axovant from the offering are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.  All of the common shares are being offered by Axovant. In connection with this offe
Apr 10, 2017 05:05 pm ET
Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares
BASEL, Switzerland, April 10, 2017 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON) ("Axovant"), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that it has commenced an underwritten public offering of $100 million of its common shares. All of the common shares are being offered by Axovant. In connection with this offering, Axovant expects to grant the underwriters a 30-day option to purchase up to an additional $15 million of its common shares in the offering on the same terms and conditions.
Apr 10, 2017 09:15 am ET
Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors
BASEL, Switzerland, April 10, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that David Hung, MD, has been named Chief Executive Officer of Axovant Sciences, effective April 7, 2017. Dr. Hung, who also joined Axovant's Board of Directors, succeeds founding Chief Executive Officer Vivek Ramaswamy. Mr. Ramaswamy will continue to serve on Axovant's Board of Directors and will lead parent company and majority owner Roivant Sciences as its full-time Chief Executive Officer.
Mar 21, 2017 05:30 pm ET
Axovant Sciences to Present at Upcoming Scientific Meetings
BASEL, Switzerland, March 21, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at the American Association for Geriatric Psychiatry (AAGP) Annual Meeting being held in Dallas March 24-27 and at the American Academy of Neurology (AAN) Annual Meeting being held in Boston April 22-28.
Mar 20, 2017 05:35 pm ET
Axovant Sciences Announces Presentation Time Change at Oppenheimer Healthcare Conference
BASEL, Switzerland, March 20, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced a change to the company's presentation time at the Oppenheimer 27th Annual Healthcare Conference.
Feb 27, 2017 04:30 pm ET
Axovant Sciences to Present at Upcoming Investor Conferences
BASEL, Switzerland, Feb. 27, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at three investor conferences:
Feb 14, 2017 04:15 pm ET
Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended December 31, 2016
  
Feb 13, 2017 07:00 am ET
Axovant Sciences Announces Preliminary Results from Interim Analysis of Phase 2 Study Testing Investigational Drug Nelotanserin in Lewy Body Dementia Patients
BASEL, Switzerland, Feb. 13, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced preliminary results from the planned interim analysis of the first 11 patients to complete its Phase 2 study of nelotanserin in Lewy body dementia patients. Based on these interim results, Axovant plans to expand patient recruitment in this study and will begin preparations for a Phase 3 registration program expected to start in the second half of 2017.
Feb 03, 2017 07:00 am ET
Axovant Sciences Announces $55.0 Million Venture Debt Financing from Hercules Capital
BASEL, Switzerland, Feb. 3, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that it has entered into a $55.0 million debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"), a leader in customized debt financing for companies in life sciences and technology-related markets.
Jan 25, 2017 04:30 pm ET
Axovant Sciences to Present at Upcoming Investor Conferences
BASEL, Switzerland, Jan. 25, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at two investor conferences:
Jan 09, 2017 07:00 am ET
Axovant Sciences Announces Pipeline Program Updates and Presentation at 35th Annual J.P. Morgan Conference
BASEL, Switzerland, Jan. 9, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced updates that highlight recent advancement within its clinical programs.
Dec 09, 2016 04:15 pm ET
Axovant Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimer's Disease Maintain Independence Longer
HAMILTON, Bermuda, Dec. 9, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced a new analysis of the data from a Phase 2b trial evaluating treatment with intepirdine (RVT-101), combined with standard of care donepezil, compared with donepezil plus placebo in people with mild-to-moderate Alzheimer's disease. This analysis indicates that the addition of intepirdine to treatment was associated with reduced progression in dependence (as assessed by Dependence Level based on the Dependenc
Dec 05, 2016 04:30 pm ET
Axovant to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimer's Disease at CTAD 2016
HAMILTON, Bermuda, Dec. 5, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that data on the investigational use of intepirdine for the treatment of Alzheimer's disease will be presented at the 2016 Clinical Trials in Alzheimer's Disease (CTAD) Meeting on Friday, December 9, 2016 in San Diego. Intepirdine presentations at CTAD will show results of both simple and complex measures of activities of daily living (ADLs) and overall functional dependence – important indicators of treat
Nov 07, 2016 04:15 pm ET
Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Second Fiscal Quarter and First Half Ended September 30, 2016
HAMILTON, Bermuda, Nov. 7, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced corporate updates and reported financial results for the second fiscal quarter and first half ended September 30, 2016.
Nov 01, 2016 05:30 pm ET
Axovant Sciences to Present at Upcoming Investor Conferences
HAMILTON, Bermuda, Nov. 1, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at three investor conferences:
Oct 19, 2016 05:01 pm ET
Patrick Machado Joins Board of Directors of Roivant Sciences
HAMILTON, Bermuda, Oct. 19, 2016 /PRNewswire/ -- Roivant Sciences Ltd., an innovative biopharmaceutical company focused on developing promising drug candidates to improve the lives of patients and their families, has expanded its Board of Directors through the appointment of Patrick Machado as its second independent director. Prior to joining the board of Roivant Sciences, Mr. Machado was a co-founder of Medivation and served as its Chief Financial Officer from 2004 to 2014. He also served as a director of Medivation through September 2016.
Sep 26, 2016 09:00 am ET
Axovant Sciences Receives FDA Fast-Track Designation for Intepirdine as an Investigational Treatment for Dementia with Lewy Bodies
HAMILTON, Bermuda, Sept. 26, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company has received Fast Track designation for its Investigational New Drug (IND) application for intepirdine in the treatment of dementia with Lewy bodies from the U.S. Food and Drug Administration (FDA).
Sep 21, 2016 09:00 am ET
Doctors Say Yearly Memory Evaluations are Critical to Early Diagnosis, Effective Treatment of Alzheimer's Disease
NEW YORK, Sept. 21, 2016 /PRNewswire/ -- Memory evaluations are critical to the early diagnosis and effective treatment of people with Alzheimer's disease, according to Dr. Gary Small, director of geriatric psychiatry at UCLA's Semel Institute for Neuroscience and Human Behavior.
Sep 06, 2016 05:30 pm ET
Axovant Sciences to Present at the Morgan Stanley Global Healthcare Conference
HAMILTON, Bermuda, Sept. 6, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at the Morgan Stanley Global Healthcare Conference on September 13 at 5:15 p.m. EDT.
Aug 31, 2016 05:30 pm ET
Axovant Sciences to Present at the Baird 2016 Global Healthcare Conference
HAMILTON, Bermuda, Aug. 31, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at the Baird 2016 Global Healthcare Conference on September 7 at 10:50 a.m. EDT.
Aug 15, 2016 05:15 pm ET
Axovant Sciences Announces Expansion of Dementia Pipeline and Reports Financial Results for the First Fiscal Quarter Ended June 30, 2016
HAMILTON, Bermuda, Aug. 15, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced corporate updates and reported financial results for the first fiscal quarter ended June 30, 2016.
Jul 24, 2016 09:00 am ET
Alzheimer's Experts Call for End to Under-Treatment of Disease
TORONTO, July 24, 2016 /PRNewswire/ -- Several physicians recognized for their contributions to clinical research and advances in the treatment of people with Alzheimer's disease today called for immediate changes to how healthcare professionals approach the management of the disease.
Jul 18, 2016 05:30 pm ET
Axovant Sciences Announces Presentations and Sponsored Symposium at the 2016 Alzheimer's Association International Conference
HAMILTON, Bermuda, July 18, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, announced today that the company will host a symposium and make four poster  presentations at the 2016 Alzheimer's Association International Conference (AAIC) being held in Toronto July 24-28.
Jul 13, 2016 05:01 pm ET
Roivant Sciences Appoints Professor Andrew Lo, PhD as Independent Director
HAMILTON, Bermuda, July 13, 2016 /PRNewswire/ -- Roivant Sciences Ltd. ("Roivant"), a biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the lives of patients and their families, has expanded its Board of Directors through the appointment of Professor Andrew Lo, PhD as an independent director. This appointment follows the closing of Roivant's private financing led by Viking Global Investors.
Jun 15, 2016 11:30 am ET
Axovant Sciences to Present at the JMP Securities Life Sciences Conference
HAMILTON, Bermuda, June 15, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced an upcoming presentation at the JMP Securities Life Sciences Conference on June 22 at 10:30 a.m. EDT.
Jun 06, 2016 09:00 am ET
Axovant Sciences Announces 2015 Fiscal Year-End Financial Results and Corporate Updates
HAMILTON, Bermuda, June 6, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today reported financial results for the fourth fiscal quarter and twelve months ended March 31, 2016.
May 13, 2016 07:59 am ET
Axovant Sciences Appoints Dr. Gary P. Pisano to Board of Directors
HAMILTON, Bermuda, May 13, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced Gary P. Pisano has joined its Board of Directors and will also serve as a member of the Board's Audit Committee. Gary Pisano is the Harry E. Figgie Professor of Business Administration at the Harvard Business School and has been on the Harvard faculty since 1988. His work has focused on a wide range of topics including pharmaceutical research and development processes.
May 09, 2016 05:00 pm ET
Axovant Sciences to Present at Upcoming Investor Conferences
HAMILTON, Bermuda, May 9, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at two investor conferences:
Apr 19, 2016 08:30 am ET
Call to Action for Participation in Clinical Trials is Topic of Symposium at Alzheimer's Disease International Conference 2016
HAMILTON, Bermuda, April 19, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON) today announced it is sponsoring a symposium at the Alzheimer's Disease International Conference 2016: "Alzheimer's Community Call to Action: Developing New Treatments Through Clinical Trial Participation." 
Apr 04, 2016 05:30 pm ET
Axovant Sciences to Present at the Goldman Sachs Alzheimer's Symposium
HAMILTON, Bermuda, April 4, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at the Goldman Sachs Alzheimer's Symposium on April 11 at 11:25 a.m. EDT.
Feb 23, 2016 04:30 pm ET
Axovant Sciences to Present at Upcoming Investor Conference
HAMILTON, Bermuda, Feb. 23, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at the Cowen and Company 36th Annual Health Care Conference on March 8 at 9:20 a.m. EST.
Feb 09, 2016 04:15 pm ET
Axovant Sciences Announces Launch of First-in-Class Clinical Programs for Lewy Body Dementia and Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2015
HAMILTON, Bermuda, Feb. 9, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced further details of three new clinical trials to address cognitive, behavioral and functional aspects of Lewy body dementia, a disease affecting approximately 1.4 million people in the U.S. Two out of the three studies were recently initiated and the third is expected to start later this quarter. In addition, the Company reported financial results for the third fiscal quarter and nine months ended December
Jan 27, 2016 09:00 am ET
Axovant Sciences to Present at Upcoming Investor Conferences
HAMILTON, Bermuda, Jan. 27, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at two upcoming investor conferences:

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More